Clinical Trial Update: Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) [Phase 2]

View source ↗

Summary

A Phase 2 trial (ROTATE) evaluating talquetamab and teclistamab in newly diagnosed multiple myeloma is currently recruiting, aiming to engage T-cells to elimina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Talquetamab (talquetamab)
• Teclistamab (teclistamab)

Snippet

Sponsor: Noffar Bar | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING